Dideoxynucleoside HIV reverse transcriptase inhibitors and drug-related hepatotoxicity: a case report. 2007

Giuseppe Lapadula, and Ilaria Izzo, and Silvia Costarelli, and Giuliana Cologni, and Luisa Bercich, and Salvatore Casari, and Marco Gambarotti, and Carlo Torti
Institute of Infectious and Tropical Diseases, University of Brescia, Italy. torti.carlo@libero.it.

This report regards the case of a 43 year-old HIV-positive woman who developed an episode of serious transaminase elevation during stavudine-including antiretroviral therapy. Diagnostic assessment ruled out hepatitis virus co-infection, alcohol abuse besides other possible causes of liver damage. No signs of lactic acidosis were present. Liver biopsy showed portal inflammatory infiltrate, spotty necrosis, vacuoles of macro- and micro-vesicular steatosis, acidophil and foamy hepatocytes degeneration with organelles clumping, poorly formed Mallory bodies and neutrophil granulocytes attraction (satellitosis). A dramatic improvement in liver function tests occurred when stavudine was discontinued and a new antiretroviral regimen with different nucleoside reverse transcriptase inhibitors was used. The importance of considering hepatotoxicity as an adverse event of HAART including stavudine, even in absence of other signs of mitochondrial toxicity should therefore be underlined. Liver biopsy may provide further important information regarding patients with severe transaminase elevation, for a better understanding of the etiology of liver damage.

UI MeSH Term Description Entries

Related Publications

Giuseppe Lapadula, and Ilaria Izzo, and Silvia Costarelli, and Giuliana Cologni, and Luisa Bercich, and Salvatore Casari, and Marco Gambarotti, and Carlo Torti
August 2004, Journal of acquired immune deficiency syndromes (1999),
Giuseppe Lapadula, and Ilaria Izzo, and Silvia Costarelli, and Giuliana Cologni, and Luisa Bercich, and Salvatore Casari, and Marco Gambarotti, and Carlo Torti
May 2003, Seminars in liver disease,
Giuseppe Lapadula, and Ilaria Izzo, and Silvia Costarelli, and Giuliana Cologni, and Luisa Bercich, and Salvatore Casari, and Marco Gambarotti, and Carlo Torti
December 1987, Biochemical pharmacology,
Giuseppe Lapadula, and Ilaria Izzo, and Silvia Costarelli, and Giuliana Cologni, and Luisa Bercich, and Salvatore Casari, and Marco Gambarotti, and Carlo Torti
June 2007, Applied microbiology and biotechnology,
Giuseppe Lapadula, and Ilaria Izzo, and Silvia Costarelli, and Giuliana Cologni, and Luisa Bercich, and Salvatore Casari, and Marco Gambarotti, and Carlo Torti
October 2022, European journal of medicinal chemistry,
Giuseppe Lapadula, and Ilaria Izzo, and Silvia Costarelli, and Giuliana Cologni, and Luisa Bercich, and Salvatore Casari, and Marco Gambarotti, and Carlo Torti
April 2002, Journal of acquired immune deficiency syndromes (1999),
Giuseppe Lapadula, and Ilaria Izzo, and Silvia Costarelli, and Giuliana Cologni, and Luisa Bercich, and Salvatore Casari, and Marco Gambarotti, and Carlo Torti
January 1994, Biochemical pharmacology,
Giuseppe Lapadula, and Ilaria Izzo, and Silvia Costarelli, and Giuliana Cologni, and Luisa Bercich, and Salvatore Casari, and Marco Gambarotti, and Carlo Torti
January 2008, Advances in pharmacology (San Diego, Calif.),
Giuseppe Lapadula, and Ilaria Izzo, and Silvia Costarelli, and Giuliana Cologni, and Luisa Bercich, and Salvatore Casari, and Marco Gambarotti, and Carlo Torti
June 2008, Virus research,
Giuseppe Lapadula, and Ilaria Izzo, and Silvia Costarelli, and Giuliana Cologni, and Luisa Bercich, and Salvatore Casari, and Marco Gambarotti, and Carlo Torti
January 2000, Advances in pharmacology (San Diego, Calif.),
Copied contents to your clipboard!